Human pharmacokinetics of WR-2721.
Publication/Presentation Date
8-1-1986
Abstract
The pharmacokinetic properties of WR-2721 were investigated in 13 cancer patients given a 150 mg/M2 intravenous bolus dose of the drug. An average plasma clearance value of 2.17 L/min was obtained. Very little of the drug or the two metabolites, WR-1065 and WR-33278, were excreted in urine obtained after the blood collection schedule. Plasma concentrations of WR-2721 decreased by 94% within 6 minutes of drug administration. The mean value of 6.44 L obtained for the steady-state volume of distribution indicates that the extravascular space occupied by the drug is small. These observations suggest that in human cancer patients, WR-2721 is rapidly taken up by tissues and converted to metabolites.
Volume
12
Issue
8
First Page
1501
Last Page
1504
ISSN
0360-3016
Published In/Presented At
Shaw, L. M., Turrisi, A. T., Glover, D. J., Bonner, H. S., Norfleet, A. L., Weiler, C., & Kligerman, M. M. (1986). Human pharmacokinetics of WR-2721. International journal of radiation oncology, biology, physics, 12(8), 1501–1504. https://doi.org/10.1016/0360-3016(86)90203-8
Disciplines
Medicine and Health Sciences
PubMedID
3019968
Department(s)
Department of Medicine
Document Type
Article